Quantcast

Latest Transplantation medicine Stories

2013-12-30 04:20:18

HORSHOLM, Denmark, Dec. 30, 2013 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO), today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the marketing and sale of Envarsus(®) (formerly LCP-Tacro(TM)) for the prevention of organ rejection in kidney transplant recipients. The submission is based on the entire data set from the company's clinical development program that comprised 25 studies and...

2013-12-12 23:04:33

Pioneering Work Receives $3.3 Million Grant From National Institutes of Health Charlottesville, VA (PRWEB) December 12, 2013 Groundbreaking research at the University of Virginia School of Medicine that aims to dramatically increase the number of lungs that can be used for transplant has received a $3.3 million grant from the National Institutes of Health. The work seeks to use a drug developed at UVA to rehabilitate lungs that are currently deemed unusable. It could allow doctors, for...

Engineered Immune Cells Fight Cancer
2013-12-09 14:30:13

Brett Smith for redOrbit.com - Your Universe Online Researchers from the University of Pennsylvania and the Children’s Hospital of Philadelphia have been able to reprogram the body’s immune system to fight leukemia, with 89 percent of children and adults in a series of clinical trials showing no evidence of cancer after receiving a personalized cell therapy. The findings from the first 59 patients to receive this cutting-edge therapy, known as CTL019, were presented during the...

2013-12-09 14:08:58

Bortezomib (Velcade) reduces GVHD, boosts survival Adding bortezomib (Velcade) to standard preventive therapy for graft-versus-host-disease (GVHD) results in improved outcomes for patients receiving stem-cell transplants from mismatched and unrelated donors, according to researchers from Dana-Farber Cancer Institute. In a new phase 2 trial, patients treated with bortezomib had lower rates of severe acute GVHD and treatment-related mortality, and experienced better one-year overall...

2013-12-09 10:45:08

Patients with myelodysplastic syndromes (MDS) who were as old as 74 fared as well with stem cell transplantation as did patients in the 60-to-65 age range, according to a study from Dana-Farber Cancer Institute presented at the annual meeting of the American Society of Hematology. "This is good evidence that age alone should not limit who should get a transplant for MDS," said Gregory Abel, MD, MPH, a medical oncologist at Dana-Farber. "Calendar age is less important than other measures,...


Latest Transplantation medicine Reference Libraries

Bone Marrow Transplantation (journal)
2012-06-04 20:00:41

Bone Marrow Transplantation is a peer-reviewed medical journal published monthly by Nature Publishing Group. As of May 2012, the editor-in-chief is J.M. Goldman (UK). The journal publishes high quality, original research that addresses all aspects of basic biology and clinical use of haemopoietic stem cell transplantation in humans. The broad scope of the journal thus encompasses topics such as stem cell biology, kinetics and cytokine control, transplantation immunology, HLA and matching...

More Articles (1 articles) »
Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'